Anacor (ANAC) Approves 3.25M Common Offering
Anacor Pharmaceuticals (Nasdaq: ANAC), today announced the sale of 3.25 million shares of its common stock for gross proceeds of $21,450,000 pursuant to an underwriting agreement with Canaccord Genuity acting as the sole bookrunner. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 487,500 shares of common stock to cover over-allotments, if any.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Canaccord Genuity Downgrades 3D Systems (DDD) to Hold
- Lipocine (LPCN) Prices 4.65M Common at $6.50/Sahre
- Energous (WATT) Files $75M Mixed Shelf
Create E-mail Alert Related CategoriesEquity Offerings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!